Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study

Care.diabetesjournals.org:  March 26, 2012.

OBJECTIVE Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP). We examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up.

RESEARCH DESIGN AND METHODS The randomized double-blind clinical trial of metformin or placebo followed by a 7–8-year open-label extension and analysis of adverse events, tolerability, and the effect of adherence on change in weight and waist circumference. Read More

National Minority Quality Forum
Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2024 National Minority Quality Forum, Inc. All Rights Reserved.